Pro-Pe adhesive tablet

Phase 2Active

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ulcer, Aphthous

Conditions

Ulcer, Aphthous

Trial Timeline

— → May 1, 2007

NCT ID

NCT00281723

About Pro-Pe adhesive tablet

Pro-Pe adhesive tablet is a phase 2 stage product being developed by Advanced Medical Solutions Group for Ulcer, Aphthous. The current trial status is active. This product is registered under clinical trial identifier NCT00281723. Target conditions include Ulcer, Aphthous.

What happened to similar drugs?

18 of 20 similar drugs in Ulcer, Aphthous were approved

Approved (18) Terminated (5) Active (2)

✅Azathioprine + PlaceboCelltrionApproved

✅Filgotinib MaleateEisaiApproved

✅E0671 + rabeprazole sodium + E0671 placeboEisaiApproved

✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved

✅AdalimumabAbbVieApproved

✅Esomeprazole SodiumAstraZenecaApproved

✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00281723	Phase 2	Active	—	May 1, 2007	Ulcer, Aphthous

Competing Products

20 competing products in Ulcer, Aphthous

See all competitors

Product	Company	Stage	Hype Score
CHF6467 active	Comac Medical	Phase 1/2	22
Mirikizumab SC + Mirikizumab IV + Placebo SC	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 2	35
Azathioprine + Placebo	Celltrion	Approved	35
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Tacrolimus	Astellas Pharma	Phase 3	40
tacrolimus + Placebo	Astellas Pharma	Phase 3	40
E3810 + E3810 + Teprenone	Eisai	Phase 2/3	38
Filgotinib Maleate	Eisai	Approved	50
AJM300 + Placebo	Eisai	Phase 3	40
E0671 + rabeprazole sodium + E0671 placebo	Eisai	Approved	43
GSK3050002 + Placebo	Eisai	Phase 1	29
Rabeprazole + Rabeprazole	Eisai	Phase 2/3	38
adalimumab + placebo	Eisai	Phase 3	40
E6007 + Placebo	Eisai	Phase 2	35
Pariet	Eisai	Pre-clinical	26
KHK4083 + Placebo	Kyowa Kirin	Phase 2	35
KHK4083 + Placebo	Kyowa Kirin	Phase 1	29
Arm1 + Arm 2	Zydus Lifesciences	Phase 2	35